- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Introduction
Hepatitis B virus (HBV) remains a major global health problem and is attributable to 780,000 deaths each year, despite the availability of a vaccine (58). More than 240 million people worldwide have chronic HBV infection, which can lead to cirrhosis, hepatocellular carcinoma (HCC), and liver failure (30,47). While the majority of adult HBV infections resolve, 80–90% of infected neonates develop chronic infection and 15–25% die from HBV-related liver disease or cancer (58). The majority of patients with chronic HBV infection do not develop liver disease and are said to be asymptomatic carriers. However, as many as 20% of patients in the immune control phase of chronic HBV infection develop reactivation of the virus and cirrhosis within 5 years (25,43,46). Therefore, although a vaccine exists with 95% efficacy, new treatments are urgently required to treat the vast numbers of HBV-infected patients worldwide who are at risk of HBV-related liver cirrhosis and cancer (58).
Resolution of HBV infection is associated with strong, polyclonal, and multi-specific CD8+ cytotoxic T-lymphocyte (CTL) responses directed against multiple viral epitopes, while chronic HBV infection is characterized by lower numbers and lower potency of HBV-specific CTLs (38,43,46,55). Inefficient T cell priming by dendritic cells (21,40), immunomodulation by regulatory T cells (28,54), and clonal exhaustion due to upregulation of inhibitory receptors, such as PD-1 (27,59), have been implicated as factors that contribute to the inadequate T cell responses. Moreover, CD8+ CTL-mediated cytotoxicity is strongly implicated in HBV-related liver damage but does not appear to play a major role in eliminating the virus, while IFN-γ produced by virus-specific CTLs and natural killer (NK) cells are thought to mediate clearance of HBV by interfering with viral replication and by recruiting other antigen-nonspecific effector cells (13,31,36,38,55). Therefore, the ideal immune response against HBV must control viral replication but limit hepatocyte cytotoxicity and immune-mediated liver damage.
Roles for γδ T cells in antiviral immune responses have been reported for cytomegalovirus (17,32), Epstein–Barr virus (18), human immunodeficiency virus (HIV) (45), and herpes simplex virus (39) infections. γδ T cells have also been implicated in immune responses to hepatitis C virus (HCV) and are thought to play a role in liver injury associated with the virus (41,56). Sing et al. (50) reported that γδ T cells were expanded in the blood of patients with HBV infection who seroconverted. Subsequently, Chen et al. (10,11) reported that Vδ2 T cells, the most abundant subset of γδ T cells in human blood and liver (37), are depleted in patients with chronic HBV infection and in patients who develop HBV-associated acute-on-chronic liver failure (HBV-ACLF). In contrast, Vδ1 T cells, the most abundant γδ T cell subset in the intestine, were expanded in the blood of patients with HBV-ACLF. γδ from HBV-ACLF patients exhibited enhanced cytotoxicity and inflammatory cytokine production compared to their counterparts in chronic HBV patients and healthy controls, suggesting that γδ T cells play a role in liver injury in HBV-ACLF (10).
In the present study, the potential role of γδ T cell subsets in immunity against HBV in the absence of liver injury was investigated by studying a cohort of patients with persistent HBV infection (HBsAg-positive) but low viral burden (<20,000 copies/mL) and no evidence of liver disease (alanine aminotransferase [ALT] <70 IU/mL). This patient cohort can be considered as having an efficient immune response against HBV, which is under sufficient regulatory control and does not cause significant pathology but fails to eliminate the virus completely (34). The frequencies, differentiation status, and IFN-γ production of the Vδ1+ and Vδ2+ subsets of γδ T cells were examined to assess, for the first time, their potential roles in controlled asymptomatic HBV infection. |
|